Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?
J. Clin. Invest. Vinayakumar Siragam, et al. 115:155 doi:10.1172/JCI22753 [
Go to this article.]
Figure 1Pretreatment of mice with soluble OVA + anti-OVA ameliorates ITP. CD1 mice were pretreated by intravenous injection of 1 mg OVA that had been preincubated with the indicated dose of anti-OVA (gray bars), followed 24 hours later by injection of 2 μg anti-platelet antibody. The
x axis denotes the treatment;
y axis denotes platelet counts taken 24 hours after injection with anti-platelet antibody. Normal, unmanipulated mice (the white horizontal bar represents the mean platelet count ± 1 SEM); ITP, mice injected with antiplatelet antibody only; ITP + IVIg, mice pretreated with 50 mg IVIg followed by antiplatelet antibody;
n = 9 mice for each group from 3 independent experiments.
#P < 0.001 vs. ITP mice. Data are presented as mean ± SEM.
